Bloodstream Infection Testing Market Analysis

Bloodstream Infection Testing Market Analysis

To get key market trends

  Download Free Sample

The market by product is categorized into reagents & consumables, and instruments. The reagents and consumables segment garnered USD 737.1 million revenue in 2023.
 

• This growth is attributed to ongoing advancements in technologies, such as molecular and immunological reagents, multiplex assays for simultaneous pathogen detection, etc. The key developments include the evolution of advanced reagent technologies, particularly in molecular and genetic testing, to enhance diagnostic accuracy.
   
• The demand for consumables related to point-of-care testing is on the rise, and there's a notable integration of artificial intelligence and bioinformatics for enhanced data analysis. Innovations in packaging for stability, a focus on environmentally friendly options, and collaborations for product development underscore the market's adaptability.
   

Based on sample type, the bloodstream infection testing market is segmented into whole blood and blood culture. The blood culture segment accounted for over 72.6% business share in 2023 and is anticipated to witness significant growth.
 

• Blood culture tests are essential for diagnosis of several infections, including fungal, and bacterial, mycobacterial infections. Both automated and manual techniques are used by healthcare professionals to detect these infections.
   
• Further, the efficiency and speed of obtaining results in the blood culture segment have been significantly boosted by the introduction of automated blood culture systems, enhanced bottle designs, and quicker detection methods. This enhancement has further strengthened the dominance of the blood culture segment.
   

The bloodstream infection testing market by technology is categorized into PCR, mass spectroscopy, in situ hybridization, and other technologies. The PCR segment accounted for around USD 457.1 million revenue size in 2023.
 

• The PCR market is anticipated to develop due to several factors, including the growing frequency of infectious and chronic diseases, the need for more sophisticated bloodstream infection detection techniques, and the expansion of forensic and research laboratories is anticipated to accelerate the segmental growth.
   
• Moreover, the development of technologically advanced PCR tests, increasing prevalence of targeted diseases, government initiatives, and application expansion of existing technologies are projected to drive the segment.
   

Based on end-use, the bloodstream infection testing market is segmented into hospitals & diagnostic centers, academic & research institutes, and other end-users. The hospitals & diagnostic centers segment accounted for over 45.3% business share in 2023 and is anticipated to witness significant growth during the forecast period.
 

• Bloodstream infections are still very difficult to diagnose and treat, but hospitals are at the forefront of this field. Accurate and fast bloodstream infection testing is becoming more and more important in order to guide treatment decisions in light of the growing number of sepsis cases and hospital-acquired infections. This propels the demand for bloodstream infection testing services in hospitals.
   
• To improve and expedite their bloodstream infection testing capabilities, hospitals frequently work with diagnostic labs and testing suppliers. These partnerships combine the knowledge and assets of the two organizations, improving patient care, testing capacity, and diagnostic accuracy. Because of these collaborations, the market is growing and there is a greater demand for blood testing services.
   

North America bloodstream infection testing market accounted for USD 381.6 million revenue in 2023 and is predicted to witness substantial market growth over the analysis timeline.
 

• The growth is majorly owing to the region's increasing disposable income, favorable reimbursement policies, highly developed health infrastructure, product launches and increasing strategic initiatives by the major companies operating in the market.
   
• Furthermore, rising prevalence of infectious diseases and awareness regarding early disease diagnosis will drive the market trends.